Omalizumab, a recombinant anti-IgE monoclonal antibody that has demonstrated efficacy in asthma treatments176, has been found to reduce not only the IgE concentration but also significantly reduced the frequency of IL-13-secreting CD8 T cells in patients with allergic asthma177. The gene discussed is IGHE; the disease is asthma.